Dying to survive: harnessing inflammatory cell death for better immunotherapy
Trends in Cancer · 2025
DOI: 10.1016/j.trecan.2025.01.012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025. Verfasst von Long Cheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, C…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Inflammation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 177 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy has transformed cancer treatment paradigms, but its effectiveness depends largely on the immunogenicity of the tumor. Unfortunately, the high resemblance of cancer to normal tissues makes most tumors immunologically 'cold', with a poor response to immunotherapy. Danger signals are critical for breaking immune tolerance and mobilizing robust, long-lasting antitumor immunity. Recent studies have identified inflammatory cell death modalities and their power in providing danger signals to trigger optimal tumor suppression. However, key mediators of inflammatory cell death are preferentially silenced during early tumor immunoediting. Strategies to rejuvenate inflammatory cell death hold great promise for broadening immunotherapy-responsive tumors. In this review, we examine how inflammatory cell death enhances tumor immunogenicity, how it is suppressed during immunoediting, and the potential of harnessing it for improved immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China; Peking-Tsinghua Center for Life Sciences, Peking University, Bei…
- Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, School of Life Sciences, Peking University, Beijing, 100871, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cheng, L., Wang, Y., & Zhang, Y. (2025). Dying to survive: harnessing inflammatory cell death for better immunotherapy. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.01.012
Vancouver
Cheng L, Wang Y, Zhang Y. Dying to survive: harnessing inflammatory cell death for better immunotherapy. Trends in Cancer. 2025. doi:10.1016/j.trecan.2025.01.012
BibTeX
@article{Cheng2025,
author = {Cheng, Long and Wang, Yibo and Zhang, Ying},
title = {Dying to survive: harnessing inflammatory cell death for better immunotherapy},
journal = {Trends in Cancer},
year = {2025},
doi = {10.1016/j.trecan.2025.01.012}
}
EUVIMED